Chongqing Pharmaceutical subsidiary gets clinical trial green light for key drug

Chongqing Pharmaceutical announced today that its subsidiary, Chongqing Pharmaceutical (Group) Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Salted Prasugrel Tablets. The drug aims to prevent blood clot formation in patients with acute coronary syndrome, stable angina, and old myocardial infarction who undergo percutaneous coronary intervention.

The clinical trial application was approved on June 23, 2025. This approval signifies that the drug meets the registration requirements for domestic production, paving the way for further development. Salted Prasugrel Tablets, originally developed by Daiichi Sankyo Co., Ltd., are a third-generation ADP activation inhibitor for platelet aggregation and are already available in over 70 countries globally, though not yet in China.

Chongqing Pharmaceutical acquired the technology and exclusive patent rights for Salted Prasugrel Tablets from Daiichi Sankyo Co., Ltd. The company initially submitted a listing registration application in August 2021, but proactively withdrew it in July 2023 to refine the application materials. This latest approval marks a significant step forward, though the company cautions that drug development involves a lengthy and complex process with inherent uncertainties.